Perbandingan Angka Kematian Terapi Antiviral Favipiravir dan Remdesivir pada Pasien COVID-19 Di RSUP Dr. Sardjito Yogyakarta

https://doi.org/10.22146/jmpf.77288

Nova Satriyani(1), Fita Rahmawati(2*), Tri Murti Andayani(3)

(1) Magister Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada
(2) Departemen Farmakologi dan Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada
(3) Departemen Farmakologi dan Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada
(*) Corresponding Author

Abstract


Antiviral treatment for SARS-CoV2 (Severe Acute Respiratory Syndrome Coronavirus-2) is still being studied for its effectivity. The antivirals in the July 3, 2021 edition of the COVID-19 management guidelines, namely favipiravir and remdesivir, are used for moderate, severe and critical degrees. The study compares the mortality rate of COVID-19 patients taking the antivirals favipiravir and remdesivir. This research is a retrospective cohort study conducted at RSUP Dr. Sardjito Yogyakarta. The data was from the medical records of patients diagnosed with moderate, severe, and critical degrees of COVID-19 treated during the January-December 2021 period. Ninety-nine patients (50.8%) used favipiravir, while 97 patients (49.5%) used remdesivir. Chi-square analysis and multiple logistic regression were used to determine the relationship between research variables. Study subjects with the highest percentage of age 46-65 years (65%), male sex (54,6%), comorbid diabetes mellitus and hypertension (13,3%), severe degree of severity (60,7%), and viral load CT value ≤ 29 (80,1%), the patient went home alive (61,2%), and died (38,8%). The antivirals did not affect on mortality (p > 0,05). Further research is needed with the same characteristics of the two groups involving factors of degree severity of the disease, co-morbidity, and other medication therapy.


Keywords


COVID-19; Favipiravir; Mortality; Remdesivir

Full Text:

PDF


References

  1. Gorbalenya AE, Baker SC, Baric RS, et al. Severe Acute Respiratory Syndrome-Related Coronavirus : The Species and Its Viruses – a Statement of the Coronavirus Study Group. Microbiology; 2020.
  2. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733.
  3. Pemda DIY. Pemerintahan Daerah Istimewa Yogyakarta. Pemda DIY. 2021.
  4. Yavuz SŞ, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci.:9.
  5. PDPI P PAPDI, PERDATIN, dan IDAI. Revisi Protokol Tatalaksana COVID-19 edisi 3. COVID-19. Published online 2021.
  6. Rico-Caballero V, Fernández M, Hurtado JC, et al. Impact of SARS-CoV-2 viral load and duration of symptoms before hospital admission on the mortality of hospitalized COVID-19 patients. Infection. Published online May 13, 2022.
  7. Li X, Zhong X, Wang Y, Zeng X, Luo T, Liu Q. Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis. Lazzeri C, ed. PLOS ONE. 2021;16(5):e0250602.
  8. Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India. 2020;76(4): 370- 376.
  9. Cai Q, Yang M, Liu D, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering. 2020;6(10):1192-1198.
  10. Prasithsirikul W, Pongpirul K, Sakornsakolpat P, Burana C, Phutrakool P, Pongpirul WA. Adjunctive favipiravir for severe COVID-19: a retrospective observational study of the first 41 patients in Thailand. Asian Biomed. 2020;14(3):107-110.
  11. Amirian ES, Levy JK. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. One Health. 2020;9:100128.
  12. Al-Abdouh A, Bizanti A, Barbarawi M, et al. Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. Contemp Clin Trials. 2021;101:106272.
  13. Lou L, Zhang H, Li Z, Tang B, Li Z. The Efficacy and Safety of Remdesivir in the Treatment of Patients with COVID-19: A Systematic Review and Meta-Analysis. Epidemiology; 2021.
  14. Ara Perveen R, Nasir M, Murshed M M, Naznin R, Ahmed SN. Remdesivir and Favipiravir Changes Hepato-Renal Profile in COVID-19 patients: A Cross Sectional Observation in Bangladesh. Int J Med Sci Clin Invent. 2021;8(01):5196-5201.
  15. Damayanti H, Sajinadiyasa IGK, Risni HW, Sauriasari R. The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients at Tertiary Referral Hospital, Bali, Indonesia. Kesmas Natl Public Health J. 2021;16(4).
  16. Riptasari RD, Rahem A, Purnamayanti A. Perbandingan Keberhasilan Terapi Antivirus Favipiravir dan Remdesivir pada Pasien Covid-19 di RSUD dr. Doris Sylvanus. J Surya Med. 2022;8(1):125-128.
  17. Anderson MR, Bach PB, Baldwin MR. Hospital Length of Stay for Patients with Severe COVID-19: Implications for Remdesivir’s Value. PharmacoEconomics - Open. 2021;5(1):129-131.
  18. Lemeshow S, Hosmer JrDW, Klar J, Lwanga S. Adequacy of Sample Size in Health Studies. Publ Behald World Health Organ Wiley. Published online 1990. Distributed in the U.S.A., Canada, and Japan by Liss, Chichester [England]; New York: New York, NY, USA
  19. Liu W, Zhou P, Chen K, et al. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. Can Med Assoc J. 2020;192(27):E734-E744.
  20. Noor FM, Islam MdM. Prevalence and Associated Risk Factors of Mortality Among COVID-19 Patients: A Meta-Analysis. J Community Health. 2020;45(6):1270-1282.
  21. Pradhan A, Olsson PE. Sex differences in severity and mortality from COVID-19: are males more vulnerable? Biol Sex Differ. 2020;11(1):53. doi:10.1186/s13293-020-00330-7
  22. Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update. 2005;11(4):411-423.
  23. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging. 2020;12(7):6049-6057.
  24. Bohn MK, Lippi G, Horvath A, et al. Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence. Clin Chem Lab Med CCLM. 2020;58(7):1037-1052.
  25. Shu H mei, He S, Sun Y, et al. Factors Influencing Viral Clearance in Mild COVID-19 and Clinical Characteristics of Asymptomatic Patients. Quinn FD, ed. BioMed Res Int. 2021;2021:1-9.
  26. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802.
  27. Buetti N, Trimboli P, Mazzuchelli T, et al. Diabetes mellitus is a risk factor for prolonged SARS-CoV-2 viral shedding in lower respiratory tract samples of critically ill patients. Endocrine. 2020;70(3):454-460.
  28. Cen Y, Chen X, Shen Y, et al. Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019—a multi-centre observational study. Clin Microbiol Infect. 2020;26(9):1242-1247.
  29. Kan C, Zhang Y, Han F, et al. Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis. Front Endocrinol. 2021;12:708494.
  30. Tsai PH, Lai WY, Lin YY, et al. Clinical manifestation and disease progression in COVID-19 infection. J Chin Med Assoc. 2021;84(1):3-8.
  31. Joshi S, Vora A, Venugopal K, et al. Real-World Experience with Favipiravir for the Treatment of Mild-to-Moderate COVID-19 in India. Pragmatic Obs Res. 2022;Volume 13:33-41.
  32. Solaymani-Dodaran M, Ghanei M, Bagheri M, et al. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. Int Immunopharmacol. 2021;95:107522.
  33. Gupte V, Hegde R, Sawant S, et al. Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database. BMC Infect Dis. 2022;22(1):1.
  34. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421-1424.
  35. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19. J Thromb Haemost. 2020;18(5):1023-1026.
  36. Anantyo DT, Kusumaningrum AA, Rini AE, Radityo AN, Rahardjani KB, Sarosa GI. Coronavirus Disease 2019 (COVID-19) Pada Anak (Studi Literatur). Medica Hosp J Clin Med. 2020;7(1A):344-360.
  37. PAMKI. Apakah arti Klinis Nilai Cycle Threshold pada hasil Pemeriksaan real time RT-PCR? Published online 2020.
  38. Cascella M, Rajnik M, Coumo A, Dulebohn SC, Di Napoli R. Evaluation, and Treatment of Coronavirus (COVID-19), (2021). StarPeals. Published online 2021.
  39. Shinkai M, Tsushima K, Tanaka S, et al. Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial. Infect Dis Ther. 2021;10(4):2489-2509.
  40. E Tanni1 S, Silvinato2 A, Floriano3 I, A Bacha4 H, Naime Barbosa5 A, M Bernardo6 W. Use of remdesivir in patients with COVID-19: a systematic review and meta-analysis. J Bras Pneumol. Published online February 23, 2022:e20210393.
  41. Lee S, Santarelli A, Caine K, Schritter S, Dietrich T, Ashurst J. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital’s Experience. J Osteopath Med. 2020;120(12):926-933.
  42. Lee S, Santarelli A, Caine K, Schritter S, Dietrich T, Ashurst J. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital’s Experience. J Osteopath Med. 2020;120(12):926-933.
  43. Pandita A, Gillani FS, Shi Y, et al. Predictors of severity and mortality among patients hospitalized with COVID-19 in Rhode Island. Camacho-Rivera M, ed. PLOS ONE. 2021;16(6):e0252411.
  44. Zheng X, Chen J, Deng L, et al. Risk factors for COVID-19 severity and their association with viral release: A retrospective cohort study. J Med Virol 202193952–961. Published online 2021.
  45. Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, Syrigos K. Thromboembolic risk and anticoagulant therapy in COVID‐19 patients: emerging evidence and call for action. Br J Haematol. 2020;189(5):846-847.
  46. Kim C, Kim JY, Lee EJ, et al. Clinical findings, viral load, and outcomes of COVID-19: Comparison of patients with negative and positive initial chest computed tomography. Sobh E, ed. PLOS ONE. 2022;17(3):e0264711.



DOI: https://doi.org/10.22146/jmpf.77288

Article Metrics

Abstract views : 1441 | views : 1737

Refbacks

  • There are currently no refbacks.


Copyright (c) 2023 JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

©Jurnal Manajemen dan Pelayanan Farmasi
Faculty of Pharmacy
Universitas Gadjah Mada
Creative Commons License
View My Stats